Jordan M. Rowe

Dr. Jordan M. Rowe

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2025 in Journal of the American Pharmacists Association
Verified
Journal Article
Open access
JRJordan M. Rowe
Jordan M. Rowe
SMSarah McBane
Sarah McBane
JWJackson T. Warner
Jackson T. Warner
LCLauren Cirrincione
Lauren Cirrincione
Transgender and gender-diverse (TGD) people may self-administer injectable estradiol or testosterone therapy for gender-affirming hormone therapy (GAHT). Knowledge about injection-related safety and injection adherence for TGD people remains to be determined. To determine the types of injection-related safety issues and medication adherence issues reported in the literature for TGD people on injectable GAHT. Our secondary objective was to identify opportunities for pharmacists to enhance the self-injection experience for TGD people on injectable GAHT. We examined the literature to determine the types of issues TGD people experience when prescribed injectable GAHT. We searched for English language publications in PubMed and Google Scholar from inception to 5 August 2024 (e.g., "transgender," "nonbinary," "self-inject*," "estrogens," "testosterone") and included original research publications that assessed one of three injection-related domains: Safety (injection site-related reactions or pain, psychological safety around injections), injection-related medication administration (individual self-injection practices and preferences including family or caregiver support administering injections, access to appropriate injection supplies, continuation of injections, patient-reported comfort) and teaching and assessment of injection practices by a pharmacist or other health care provider (clinic- or pharmacy-based injection counseling or follow-up assessments). We excluded articles that did not describe whether GAHT was self-injected and publications about long-acting injectable testosterone undecanoate, as trained providers administer this medication. Seven publications discussed at least one of the three injection-related domains. Investigators used various methods for assessing these elements across publications. Although self-injected GAHT was well-tolerated overall, most publications reported injection site reactions that were managed while continuing self-injected GAHT. Gaps included comprehensive teaching and assessment of individual self-injection practices long-term. Based on the types of injection-related challenges identified, pharmacists, as one of the most accessible health care providers in the United States, are well-positioned to intervene and improve the experience of patients using injectable GAHT.

23 March 2026 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
JRJordan M. Rowe
Jordan M. Rowe
ICIan Coffman
Ian Coffman
KBKylie N. Barnes
Kylie N. Barnes
Objective: To review the efficacy and safety of elinzanetant for the management of vasomotor symptoms (VMS) associated with menopause. Data Sources: Literature was identified using PubMed (1966 to January 2026), EMBASE (1973 to January 2026), and clinicaltrials.gov. Search terms included elinzanetant, VMS, and menopause, limiting trials to those published in English. Study Selection and Data Extraction: Articles selected for inclusion included trials evaluating elinzanetant for the treatment of VMS. Data Synthesis: Elinzanetant was evaluated for reduction in frequency and severity of moderate-to-severe VMS associated with menopause in 3 phase 3 trials (OASIS 1, 2, and 3) and 1 phase 3 trial in patients receiving endocrine therapy for breast cancer (OASIS 4). All studies showed significant improvements in symptom frequency at week 12 compared to placebo ( P < .001). Improvement in sleep disturbances and quality of life was also significant in OASIS 1, 2, and 4. Elinzanetant was well-tolerated, with headache, fatigue, dizziness, somnolence, abdominal pain, and rash reported as the most frequent drug-associated adverse effects. Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: Elinzanetant is the first dual neurokinin-1 and neurokinin-3 receptor antagonist approved for moderate-to-severe VMS associated with menopause. Elinzanetant offers a nonhormonal treatment option with favorable tolerability, representing a promising alternative for patients who cannot or prefer not to use hormonal therapy. Conclusion: The U.S. Food and Drug Administration approval of elinzanetant provides an additional nonhormonal option for managing moderate-to-severe VMS of menopause in patients for whom hormonal therapy is contraindicated or undesired.

23 January 2026 in Pharmacy
Verified
Journal Article
Open access
PDF file
APAbby C. Poage
Abby C. Poage
JRJordan M. Rowe
Jordan M. Rowe
MDMaryBeth A. Dameron
MaryBeth A. Dameron
ABAbigail M. Bavuso
Abigail M. Bavuso
ASAndrew J Smith
Andrew J Smith
This single health system, retrospective cohort study compared subcutaneous (SC) versus intramuscular (IM) estradiol administration in 70 adult patients with a diagnosis of gender incongruence or gender dysphoria seen in an LGBTQ Specialty Clinic within a safety-net institution between October 2018 and December 2024. The primary endpoint was patients who reached therapeutic estradiol levels at 6 months. Secondary endpoints included the incidence of sub- and supra-therapeutic and actual estradiol levels at months 3, 6, 9, and 12 and patients who received pharmacist-led injection technique education. At 6 months, the proportion of patients achieving therapeutic estradiol levels did not differ between IM and SC administration. In exploratory analyses of continuous estradiol concentrations, IM administration was associated with higher measured estradiol levels.